ICAM-Lcn2-LP

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameICAM-Lcn2-LP
Drug Alias NameICAM-Lcn2-LP
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody-Oligonucleotide conjugate > Antibody-siRNA conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody liposome conjugateSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionIntercellular adhesion molecule-1 inhibitorsNeutrophil gelatinase-associated lipocalin inhibitorsRNA interference
TargetsIntercellular adhesion molecule-1Neutrophil gelatinase-associated lipocalin
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe City College Of New York
China Registration ClassN/A

Develop Information

Active CompaniesThe City College Of New York
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A